Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Medicine (Baltimore) ; 100(33): e26997, 2021 Aug 20.
Article in English | MEDLINE | ID: mdl-34414984

ABSTRACT

BACKGROUND: Postoperative nausea and vomiting (PONV) is an undesirable complication in patients undergoing general anesthesia. Combination therapy via different mechanisms of action for antiemetic prophylaxis has been warranted for effective treatment of PONV. This study was designed to compare the prophylactic antiemetic effect between midazolam combined with palonosetron (group MP) and palonosetron alone (group P) after laparoscopic cholecystectomy surgeries. METHODS: A prospective randomized controlled trial was investigated in non-smoking female. Eighty-eight patients were randomly divided into 2 groups with 44 patients each. Group MP received 0.05 mg/kg of midazolam intravenously before induction of anesthesia whereas group P received the same volume of normal saline. Immediately after anesthetic induction, 0.075 mg of palonosetron was administered to both the groups. The incidence and severity of PONV were assessed during 2 time intervals (0-2 hours, 2-24 hours), postoperatively. RESULTS: The incidence of PONV during 24 hours after surgery was lower in group MP as compared to group P. There was also a significant difference in the use of rescue antiemetics. The severity of nausea was significantly lower in group MP as compared to group P, in the initial 2 hours after surgery. The incidence of side effects was similar between the 2 groups. CONCLUSION: In the prevention of PONV, midazolam combined with palonosetron, administered during induction of anesthesia was more effective as compared to palonosetron alone.


Subject(s)
Cholecystectomy, Laparoscopic/adverse effects , Midazolam/standards , Palonosetron/standards , Postoperative Nausea and Vomiting/prevention & control , Adjuvants, Anesthesia/standards , Adjuvants, Anesthesia/therapeutic use , Adult , Antiemetics/standards , Antiemetics/therapeutic use , Cholecystectomy, Laparoscopic/methods , Cholecystectomy, Laparoscopic/statistics & numerical data , Female , Humans , Male , Midazolam/therapeutic use , Middle Aged , Palonosetron/therapeutic use , Postoperative Nausea and Vomiting/drug therapy , Prospective Studies , Republic of Korea
2.
Article in English | MEDLINE | ID: mdl-26234474

ABSTRACT

INTRODUCTION: Sodium pentobarbital (Nembutal) is a barbiturate used in research as an anesthetic in many animal models. The injectable form of this drug has lately become difficult to procure and prohibitively expensive. Due to this lack of availability, researchers have begun to compound injectable sodium pentobarbital from so-called "nonpharmaceutical" pentobarbital. Some oversight agencies have objected to this practice, claiming a lack of quality control and degradation of the drug. We sought with this study to establish both: 1) a protocol for the preparation of injectable sodium pentobarbital, and 2) standard operating procedures to monitor the quality of the preparation and degradation of the drug over time. METHODS: Our preparation consists of a mixture of sodium pentobarbital in alkaline aqueous solution, propylene glycol, and ethanol. Pentobarbital content in this preparation was assayed by high-pressure liquid chromatography (HPLC). We also assayed pentobarbital content over time in preparations of various ages up to 6 years old. RESULTS: We determined that the drug degraded at a maximum of 0.5% per year in our preparation (alkaline water/propylene glycol/ethanol) when stored in the dark at room temperature. A yellow discoloration developed after about 2 years, which we have arbitrarily determined disqualifies the preparation from use as an anesthetic. Attempts to spectroscopically assay this discoloration were not successful. CHEMICALS: Pentobarbital sodium (CID: 14075609).


Subject(s)
Adjuvants, Anesthesia , Drug Compounding , Pentobarbital , Adjuvants, Anesthesia/administration & dosage , Adjuvants, Anesthesia/chemistry , Adjuvants, Anesthesia/standards , Animals , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Drug Compounding/methods , Drug Compounding/standards , Drug Stability , Drug Storage , Injections , Pentobarbital/administration & dosage , Pentobarbital/chemistry , Pentobarbital/standards , Spectrophotometry, Ultraviolet , Time Factors
4.
Pediatr Hematol Oncol ; 17(5): 383-8, 2000.
Article in English | MEDLINE | ID: mdl-10914048

ABSTRACT

Ketamine is a drug widely used for analgesia and sedation of children for diagnostic and therapeutic procedures. The authors investigated in a randomized controlled clinical trial if diazepam premedication would have a beneficial effect on side effects related to ketamine anesthesia for bone marrow punctures (BMPs) in children with acute lymphoblastic leukemia (ALL). Sixteen children 4 years or older at the time of BMP were eligible. The first 2 BMPs after complete remission was obtained were studied. BMPs were performed under ketamine anesthesia (1.0-1.5 mg/kg i.v.), as usual. Patients were randomized to receive 1 h before the first BMP blinded, either diazepam or placebo orally and before the second BMP the other way round. Blood pressure, heart rate, and oxygen saturation were monitored, and patients were observed for signs of anxiety, pain, and other side effects. The patients were interviewed after each BMP and asked for their preference 1 week after the second BMP. Ketamine anesthesia appeared as safe and effective after diazepam premedication as after placebo premedication. From the interviews and questionnaires, it was clear that half of the children preferred diazepam premedication because of less awful dreaming and more gradual falling asleep and waking up. Diazepam premedication may be useful for selected children with ALL receiving ketamine anesthesia for BMPs.


Subject(s)
Anesthesia/methods , Diazepam/therapeutic use , Ketamine/adverse effects , Preanesthetic Medication , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adjuvants, Anesthesia/standards , Adjuvants, Anesthesia/therapeutic use , Adolescent , Analgesics/adverse effects , Analgesics/therapeutic use , Anesthesia/standards , Blood Gas Monitoring, Transcutaneous , Bone Marrow , Child , Child, Preschool , Diazepam/standards , Female , Humans , Ketamine/therapeutic use , Male , Oxygen/blood , Pain/drug therapy , Pain/prevention & control , Precursor Cell Lymphoblastic Leukemia-Lymphoma/psychology , Punctures/adverse effects , Punctures/psychology , Sleep/drug effects , Surveys and Questionnaires
5.
Acta Anaesthesiol Scand ; 23(4): 331-5, 1979 Aug.
Article in English | MEDLINE | ID: mdl-40380

ABSTRACT

The potency and speed of onset of fazadinium and d-tubocurarine have been compared at three cumulative doses. Wtih thiopentone as the induction agent, the dose ratio fazadinium/d-tubocurarine ranged from 1.2 to 1.3 for single twitch reduction and from 1.1 to 1.2 for reduction of tetanus. The times taken for the development of 50% and 100% effect after each dose increment were not significantly different for the three doses of fazadinium and the 2nd and 3nd doses of d-tubocurarine. However, the 1st dose of d-tubocurarine was markedly slower than fazadinium to achieve a 50% and 100% effect.


Subject(s)
Adjuvants, Anesthesia/standards , Neuromuscular Junction/drug effects , Pyridinium Compounds/pharmacology , Tubocurarine/pharmacology , Adult , Aged , Female , Humans , Injections, Intravenous , Male , Middle Aged , Muscle Contraction/drug effects , Pyridinium Compounds/administration & dosage , Time Factors , Tubocurarine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...